Indications for use of Omega 3: secondary prevention of myocardial infarction (as part of combination therapy with statins, beta-blockers, antithrombotic agents, ACE inhibitors); hyperlipoproteinemia (abnormally high levels of fats and / or lipoproteins in the blood); endogenous hypertriglyceridemia (according to Fredrickson’s classification – type IV) as monotherapy as a supplement to the diet with insufficient effectiveness; mixed hyperlipidemia (according to Fredrickson’s classification – types IIb and III) in combination with statins, in cases where the concentration of triglycerides remains high.
Omega 3 composition and form of release
Available in 500 mg capsules. Each capsule contains omega-3 acids of ethyl esters (ethyl ester of eicosapentaenoic acid – 46%, ethyl ester of docosahexaenoic acid – 38%).
Omega 3 is a lipid-lowering (fat-reducing) agent based on ethyl esters of omega-3 acids.
Fatty acids of the omega-3 class – eicosapentaenoic and docosahexaenoic acids are referred to as essential (irreplaceable) fatty acids. These fatty acids improve the fluid properties of the cell membranes, increase the functional activity of the receptors of these membranes, which changes the lipid-cell interaction of lipoproteins with enzymes, lipoprotein metabolism. They delay the production of triglycerides in the liver (due to the inhibition of esterification of fatty acids). These acids contribute to a marked reduction in triglyceride levels by increasing the beta-oxidation of fatty acids by P peroxide (decreases the amount of free fatty acids available for triglyceride production). The increase in the number of high density lipoproteins is insignificant and not constant, while it is much less than after the use of fibrates.
In addition, the drug has an antiplatelet effect, which is associated with a change under its influence in the composition of lipids of cell membranes, including erythrocyte membranes, a decrease in the content of arachidonic acid in them, an increase in the amount of eicosapentaenoic acid. As a result of this, there is a decrease in the production of thromboxane A2, other derivatives of arachidonic acid (diunsaturated eicosanoids), which enhance the aggregation (pooling) of platelets, an increase in the production of tormboxane A3 from eicosapentaenoic acid, and other triunsaturated eicosanoids that do not have a proaggregant effect. No significant changes in other factors affecting blood coagulation were observed.
Also, the drug is characterized by a cardiotropic (improving heart function) effect. It is due to the antiarrhythmic effect of omega-3 polyunsaturated fatty acids, the increased amount of which in the fat bilayer of cardiomyocytes (heart cells) promotes more efficient operation of cation pumps, which helps to reduce the number of cases of ventricular tachycardia, heart fibrillation, and prevents disturbances in the electrical stability of the heart due to postinfarction cardiosclerosis …
Bo time of absorption of Omega 3 fatty acids, their metabolism occurs in 3 ways: fatty acids are delivered to the liver, where they are included in different categories of lipoproteins, then they are sent to peripheral fat stores; phospholipids of cell membranes are replaced by phospholipids of lipoproteins, as a result of which fatty acids are able to act as precursors of eicosanoids; most of the fatty acids are oxidized to provide the body’s energy needs.
Indications for use of Omega 3:
- secondary prevention of myocardial infarction (as part of combination therapy with statins, beta-blockers, antithrombotic agents, ACE inhibitors);
- hyperlipoproteinemia (abnormally high levels of fats and / or lipoproteins in the blood):
- endogenous hypertriglyceridemia (according to Fredrickson’s classification – type IV) as monotherapy as a supplement to the diet with insufficient effectiveness; mixed hyperlipidemia (according to Fredrickson’s classification – types IIb and III) in combination with statins, in cases where the concentration of triglycerides remains high.
This medication should not be used for exogenous hypertriglyceridemia (type 1 hyperchylomicronemia), allergies to the components of the drug. It is used with caution in severe liver failure, concomitant use with fibrates, anticoagulants, during surgery, severe trauma (due to the risk of increased bleeding time), in patients under 18 or over 70 years of age (safety has not been established).
It is not used in pediatrics.
Application during pregnancy and lactation
Do not use.
Method of administration and dosage
Omega 3 capsules are recommended to be taken internally with meals. For secondary prevention of myocardial infarction, it is recommended to take 2 capsules / day. For hypertriglyceridemia, the starting dose is 4 capsules / day. In the absence of a therapeutic effect, it is possible to increase the dose to 8 capsules / day. Duration of treatment – according to the doctor’s recommendation.
In connection with a moderate increase in bleeding time (especially when taking high doses), it is necessary to monitor patients receiving anticoagulants, and if necessary, an appropriate correction of the dose of anticoagulants is performed.
Consideration should be given to the increase in bleeding time in patients with a high risk of hemorrhage (surgery, severe trauma, etc.).
The available experience in the treatment of secondary endogenous hypertriglyceridemia is limited (especially in uncontrollable diabetes mellitus).
There is no clinical experience in the treatment of hypertriglyceridemia in combination with fibrates.
When taking this medication, a moderate increase in the activity of liver transaminases (ALT, AST) is possible.
In patients with impaired liver function (especially when high doses are used), regular monitoring of the functional state of the liver (AST, ALAT) is necessary.
There is no information on the use of this medication in children, patients over 70 years of age, or in patients with liver dysfunction. In patients with impaired renal function, dose adjustment is not required.
With simultaneous use with oral anticoagulants, the risk of bleeding increases.
The appointment of Omega 3 together with warfarin does not lead to any changes in blood clotting and hemorrhagic complications. However, with the combined use of these drugs or discontinuation of Omega 3 treatment, prothrombin time control is necessary.
It is not recommended to take it simultaneously with fibrates.
Overdose symptoms: the appearance of adverse reactions or an increase in their severity.
Overdose treatment: drug withdrawal, symptomatic therapy.
- Vascular disorders: lowering blood pressure.
- Co side of the gastrointestinal tract: nausea / vomiting, dyspepsia, reflux, belching with a smell or taste of fish.
- Respiratory organs: dry nose.
- Co side of the nervous system: dysgeusia (perversion of taste), dizziness, headache.
- Metabolic and nutritional disorders: hyperglycemia (increased blood sugar).
- Co side of the liver: changes in liver health indicators.
- Co side of the immune system: manifestations of allergies.
- Co side of the skin, subcutaneous fat: itchy rash, acne, urticaria.
- Infectious processes: gastroenteritis (inflammatory changes in the stomach and small intestine).
Storage conditions and periods
Store Omega 3 protected from moisture and light at a temperature of 15-25 ° C. The shelf life is two years.